Pipeline Programs
CGT Companies Tracked
Manufacturing Facilities
The U.S. residual DNA testing market size was estimated at USD 154.39 million in 2025, mainly due to the pharmaceutical and biotechnology sector, which utilizes DNA testing in multiple research and therapeutic production. The market size is predicted to increase from USD 163.93 million in 2026 due to the rising demand for cell and gene therapy and increased outsourcing to approximately USD 281.22 million by 2035, expanding at a CAGR of 6.18% from 2026 to 2035 due to automation and GMP readiness, PCR and dPCR technologies, and also because of the emerging market. The market is also driven by rigorous regulatory safety standards for biopharmaceuticals and the escalating volume of biologics and gene therapy production.
The U.S. residual DNA testing market pertains to the market for analytical assays, kits, and instruments used to detect, quantify, and characterize residual host cell DNA (rcDNA) present in biopharmaceutical products, especially biologics produced via microbial, yeast, or mammalian cell lines. Regulatory bodies such as the FDA and EMA mandate limits on residual DNA in final drug products due to potential safety concerns. Residual DNA testing ensures compliance with these safety thresholds using techniques such as qPCR, Southern blotting, and hybridization assays. It is a critical part of the quality control and release testing in biologics manufacturing, especially for monoclonal antibodies, vaccines, cell and gene therapies, and biosimilars.
Beyond standard assays, the market experiences massive growth driven by the explosion of cell and gene therapies. Advanced modalities require precise monitoring, pushing modern labs toward digital PCR technology. This innovation offers absolute quantification without standard curves, minimizing human error. Major industry leaders like Thermo Fisher Scientific, Bio-Rad Laboratories, and Merck KGaA dominate this competitive landscape. They constantly launch automated extraction kits to streamline workflows. Consequently, the commercial sector shifts from traditional methods toward high-throughput platforms. These advancements dramatically reduce processing times, helping biopharmaceutical companies accelerate their commercialization timelines while maintaining strict analytical precision across diverse therapeutic pipelines.
Financially, outsourcing to specialized contract development and manufacturing organizations fuels substantial domestic market expansion. Small biotech firms lack the expensive infrastructure required for complex internal testing and validation. Therefore, they rely heavily on third-party laboratories to meet stringent safety criteria. Specifically, the FDA enforces a strict regulatory limit of ten nanograms of residual host cell DNA per therapeutic dose. Meeting this specification requires highly sensitive, validated reagents to avoid costly batch rejections. As biopharmaceutical pipelines expand, the demand for standardized, legally compliant testing matrices increases. This economic pressure establishes long-term revenue streams for analytical instrument developers operating nationwide.
Residual DNA testing is an analytical process used to detect and quantify trace amounts of host cell DNA remaining in biologics, vaccines, gene therapies, and other biopharmaceutical products to ensure product safety, quality, and regulatory compliance.
The U.S. residual DNA testing market is growing due to increasing production of biologics, cell and gene therapies, and vaccines requiring stringent quality control. Rising regulatory emphasis on product purity and manufacturing consistency is further supporting demand. Key trends include the adoption of rapid PCR-based assays, automated analytical workflows, and high-throughput testing platforms. Future opportunities are emerging with the expansion of advanced biologics, personalized medicines, and contract testing services. Technological advancements in digital PCR, next-generation sequencing, automated sample preparation, and highly sensitive detection methods are enhancing testing accuracy, reducing turnaround time, and improving quality assurance across bioprocessing manufacturing.
U.S. residual DNA testing involves detecting and quantifying trace amounts of host cell DNA remaining in biologics, vaccines, cell therapies, and gene therapies to ensure product safety, quality, and regulatory compliance. The U.S. residual DNA testing market is expanding due to the rapid growth of biopharmaceutical manufacturing, increasing approvals of advanced therapies, and stringent FDA quality requirements. Technological advancements such as digital PCR (dPCR), real-time PCR (qPCR), next-generation sequencing (NGS), and automated analytical platforms are improving testing sensitivity and efficiency. Key trends include the adoption of high-throughput workflows, automation, and AI-enabled data analysis to streamline quality control. Future opportunities are driven by the expanding pipeline of personalized medicines, biosimilars, and regenerative therapies. Rising investments in bioprocessing infrastructure and advanced analytical technologies continue to strengthen market growth while ensuring product consistency and patient safety.
Increasing trend of early newborn screening tests, which help in detecting and preventing severe health conditions, ensuring a healthy start for the baby, which is increasing demand for residual DNA testing.
For instance,
Growing healthcare partnership, professionals adapt drug therapies to personalized genetic profiles, ensuring lower side effects and more efficient results. This supports enhancing patient experience and satisfaction and builds a truthful relationship, which drives the growth of the market.
For Instance,
Growing Adoption of Digital PCR Technology
Digital PCR is gaining momentum due to its exceptional sensitivity and precise quantification of trace residual DNA. Future adoption will increase as biopharmaceutical manufacturers seek highly accurate analytical methods to support complex biologics, gene therapies, and advanced quality control processes.
Expansion of High-Throughput Testing Automation
Biopharmaceutical laboratories are increasingly implementing automated sample preparation and high-throughput testing platforms to improve laboratory productivity. This trend will reduce turnaround times, minimize manual errors, and support large-scale biologics manufacturing with consistent analytical performance.
Rising Use of Next-Generation Sequencing (NGS)
NGS is emerging as a powerful tool for comprehensive residual DNA characterization beyond conventional detection methods. Future advancements will enable deeper genomic analysis, improve process validation, and strengthen quality assurance for next-generation biologics and cell- and gene-based therapies.
Integration of AI in the residual DNA testing drives the growth of the market as the AI-driven residual testing is a combination of convolutional neural networks and residual neural networks to efficiently extract hierarchical characteristics and comprehensive patterns from multifaceted amino acid genomic data. This supports increasing the speed of diagnosis and lowers the expenses without compromising testing accuracy and quality. AI-based testing precisely detects genomic profile mutations from multiple clones. This testing also offers a quantitative framework for examining the connection between network features and severe diseases. AI-powered algorithms streamline genomic interpretation, classifying and detecting genetic variants within seconds rather than weeks or months, enhancing diagnostic yield for genetic diseases, which drives the growth of the market.
Increasing Demand for Residual DNA
Increasing demand for residual DNA to ensure the safety and effectiveness of biopharmaceuticals goes beyond careful manufacturing. It is significant to comply with international regulatory standards to reduce risks from high residual DNA levels in products. Residual DNA typically appears in biological products when host cells are needed for production, which also contributes to the growth of the U.S. residual DNA testing market.
Major Limitation of Cell-Based Assay
Major challenges in the development and validation of residual DNA analytical assays in gene therapy. Development of these assays for complex and precise quantitation of host cell DNA and other DNA residuals needs dedicated expertise, it takes more time, and requires developing multiple documents, including method standard operating procedure (SOP), preparation qualification of significant reagents, which limits the growth of the U.S. residual DNA testing market.
Increasing Advancement in Digital Droplet PCR (ddPCR)
Residual DNA testing is essential for assessing the quality and safety of biologics, as well as for process validation, batch-to-batch variation, and GMP lot release. While real-time qPCR is the standard method for residual DNA analysis, digital droplet PCR (ddPCR) offers several key advantages. These include high sensitivity and specificity, absolute quantification without the need for a standard curve, excellent reproducibility, tolerance to PCR inhibitors, and greater efficiency compared to traditional molecular techniques. These benefits are driving growth in the U.S. residual DNA testing market.
| Table | Scope |
| Market Size in 2026 | USD 163.93 Million |
| Projected Market Size in 2035 | USD 281.22 Million |
| CAGR (2026 - 2035) | 6.18%% |
| Historical Data | 2020 - 2023 |
| Base Year | 2025 |
| Forecast Period | 2026 - 2035 |
| Measurable Values | USD Millions/Units/Volume |
| Market Segmentation | By Technology, By Application, By End User, By Sample Type |
| Top Key Players | Thermo Fisher Scientific, Merck KGaA (MilliporeSigma), Roche, Bio-Rad Laboratories, Agilent Technologies, Charles River Laboratories, Eurofins Scientific, Sartorius AG, Revvity (PerkinElmer), Lonza Group |
| Segment | Share 2025 (%) |
| Quantitative PCR (qPCR) | 42% |
| Next-Generation Sequencing (NGS) | 22% |
| Digital PCR (dPCR) | 18% |
| PicoGreen / Fluorescence Assays | 10% |
| Other Spectrophotometric & Nanodrop Methods | 8% |
The Quantitative PCR (qPCR) Segment Led the Market in 2025
The quantitative PCR (qPCR) segment led the U.S. residual DNA testing market in 2025, with a share of 42.00%, because it provides highly sensitive, accurate, and rapid detection of residual DNA in biologics, vaccines, and cell and gene therapies. Pharmaceutical and biotechnology companies rely on qPCR to meet strict regulatory expectations for product safety and quality control. Its established protocols, broad laboratory adoption, cost-effectiveness, and compatibility with high-throughput testing support routine manufacturing workflows. Continuous production of advanced biologics and increasing investments in biopharmaceutical development further strengthen demand for qPCR across research, development, validation, and commercial manufacturing applications nationwide.
The next-generation sequencing (NGS) segment held the second-largest share of 22% of the market in 2025 and is expected to grow at the fastest CAGR of 8.44% during the forecast period because it delivers comprehensive genetic analysis with exceptional sensitivity and detailed sequence information. Growing development of complex biologics, personalized medicines, and advanced cell and gene therapies is increasing demand for sophisticated DNA characterization technologies. NGS supports identification of residual DNA fragments, contamination risks, and genetic variations in a single workflow. Continuous technological improvements, declining sequencing costs, expanding bioinformatics capabilities, and increasing adoption by pharmaceutical manufacturers and research organizations are expected to accelerate future market growth significantly.
The digital PCR (dPCR) segment held a significant U.S. residual DNA testing market share of 18.00% in 2025 due to its exceptional precision, sensitivity, and ability to provide absolute DNA quantification without requiring standard calibration curves. It is increasingly preferred for detecting extremely low concentrations of residual DNA in biologics, vaccines, and gene therapy products. Growing emphasis on product quality, manufacturing consistency, and regulatory compliance supports wider adoption of dPCR across pharmaceutical laboratories. Continuous technological advancements and expanding use in analytical validation and quality assurance further contribute to sustained market demand across the U.S.
The picoGreen/fluorescence assays segment held a significant market share of 10.00% in 2025 because it offers a simple, rapid, and cost-effective approach for measuring double-stranded DNA during research and manufacturing processes. These assays are widely used for routine screening, process monitoring, and preliminary quality assessments in pharmaceutical and biotechnology laboratories. Their ease of use, compatibility with standard laboratory instruments, and ability to support high-throughput workflows make them valuable for large testing volumes. Increasing biologics production and laboratory efficiency requirements continue supporting demand for fluorescence-based assay technologies.
| Segment | Share 2025 (%) |
| Testing Kits & Reagents | 47% |
| Assay Development & Custom Services | 19% |
| Instrumentation | 15% |
| Contract Testing Services | 13% |
| Software & Data Analysis Tools | 6% |
The Testing Kits & Reagents Segment Dominated the Market in 2025
The testing kits & reagents segment led the U.S. residual DNA testing market in 2025, with a share of 47.00%, because these products are essential for routine DNA detection and quality testing during biologics, vaccines, and cell therapy manufacturing. Pharmaceutical and biotechnology companies use them regularly to ensure product safety and meet regulatory standards. Their consistent demand, easy availability, reliable performance, and compatibility with different testing methods make them a preferred choice. Growing production of biologics and increasing quality control requirements across manufacturing facilities continue to drive the use of testing kits and reagents throughout the U.S.
The assay development & custom services segment held the second-largest share of 19.00% of the market in 2025 and is expected to grow at the fastest CAGR of 8.62% during the forecast period because many pharmaceutical and biotechnology companies require customized testing solutions for different products and manufacturing processes. These services help improve testing accuracy, meet regulatory requirements, and support the development of complex biologics and advanced therapies. As more companies focus on personalized medicines and innovative biologics, demand for specialized assay development continues to rise. Increasing outsourcing activities and the need for flexible testing solutions are expected to support strong future growth across the U.S. market.
The instrumentation segment held a significant U.S. residual DNA testing market share of 15.00% in 2025 because advanced instruments are essential for accurate, reliable, and efficient DNA testing in pharmaceutical and biotechnology laboratories. Companies continue investing in modern equipment to improve testing speed, reduce errors, and support high sample volumes. Growing production of biologics, vaccines, and cell and gene therapies has increased the need for advanced laboratory systems. Continuous improvements in testing technologies and greater focus on laboratory automation are also driving demand for high-performance instruments across the U.S.
The contract testing services segment held a significant market share of 13.00% in 2025 because many pharmaceutical and biotechnology companies outsource testing to specialized laboratories with advanced expertise and regulatory experience. Outsourcing helps reduce operational costs, saves time, and provides access to skilled professionals and modern testing technologies. It also allows manufacturers to focus on product development while ensuring compliance with strict quality standards. The growing number of biologics and cell therapy projects continues to increase the demand for reliable contract testing services across the U.S.
The software & data analysis tools segment held a significant market share of 6.00% in 2025 because laboratories increasingly rely on digital tools to manage, analyze, and interpret complex testing data. These solutions help improve accuracy, reduce manual errors, and simplify regulatory documentation and reporting. As testing volumes continue to grow, pharmaceutical and biotechnology companies are investing in software that supports faster decision-making and better workflow management. The increasing use of automated laboratory systems is also driving demand for advanced data analysis and software solutions across the U.S.
| Segment | Share 2025 (%) |
| Monoclonal Antibodies & Recombinant Proteins | 38% |
| Cell & Gene Therapies | 23% |
| Vaccines | 16% |
| Viral Vectors & Gene Delivery Systems | 12% |
| Biosimilars | 7% |
| Other Biologics | 4% |
Which Application Dominated the Market in 2025?
The monoclonal antibodies & recombinant proteins segment led the U.S. residual DNA testing market in 2025, with a share of 38.00%, because these products require strict quality control throughout development and manufacturing. Residual DNA testing is an important step to ensure product safety, purity, and compliance with regulatory standards. The growing use of monoclonal antibodies for treating cancer, autoimmune diseases, and other chronic conditions has increased production across the United States. Rising investments in biopharmaceutical research, expanding manufacturing capacity, and continuous demand for innovative biologic therapies continue to support the strong adoption of residual DNA testing in this segment.
The cell & gene therapies segment held the second-largest share of 23.00% of the market in 2025 and is expected to grow at the fastest CAGR of 9.21% during the forecast period because these advanced treatments require highly sensitive testing to ensure product safety and quality. Residual DNA testing helps detect unwanted genetic material during manufacturing and supports compliance with strict regulatory requirements. Growing research activities, increasing clinical trials, and rising approvals of cell and gene therapies are driving demand for advanced testing solutions. Continued investments in regenerative medicine and personalized treatments are expected to support the fastest growth of this segment during the forecast period.
The vaccines segment held a significant market share of 16.00% in 2025 because vaccine production requires careful monitoring to ensure safety, quality, and regulatory compliance. Residual DNA testing helps manufacturers detect and control unwanted DNA that may remain after the production process. Increasing vaccine development for infectious diseases and growing investments in advanced vaccine technologies continue to support demand for reliable testing methods. The expansion of domestic manufacturing facilities and ongoing public health initiatives also contribute to the steady growth of this segment across the United States.
The viral vectors & gene delivery systems segment held a significant U.S. residual DNA testing market share of 12.00% in 2025 because these technologies are widely used in gene therapy development and advanced biologic manufacturing. Residual DNA testing is essential to ensure product safety, quality, and compliance with regulatory standards before clinical and commercial use. Growing investments in gene therapy research, increasing clinical development activities, and rising demand for advanced delivery technologies are supporting the adoption of reliable testing methods. These factors continue to strengthen the segment’s role in the U.S. market.
The biosimilars segment held a significant market share of 7.00% in 2025 because biosimilar products must meet strict quality, safety, and regulatory requirements before reaching patients. Residual DNA testing plays an important role in confirming product purity and consistency during manufacturing. The growing acceptance of biosimilars as cost-effective alternatives to biologic medicines has encouraged higher production across the United States. Increasing approvals, expanding manufacturing capabilities, and rising demand for affordable biological treatments continue to support the need for reliable residual DNA testing in this segment.
| Segment | Share 2025 (%) |
| Pharmaceutical & Biotechnology Companies | 53% |
| Contract Research & Testing Organizations | 26% |
| Academic & Research Institutions | 12% |
| Regulatory & Reference Laboratories | 9% |
Which End-User Segment Dominated the Market in 2025?
The pharmaceutical & biotechnology companies segment led the U.S. residual DNA testing market in 2025 because these companies are the primary developers and manufacturers of biologics, vaccines, biosimilars, and advanced cell and gene therapies. Residual DNA testing is an essential part of their quality control process to ensure product safety, purity, and compliance with regulatory standards. Increasing investments in biopharmaceutical research, expanding manufacturing facilities, and the growing demand for innovative therapies have strengthened the need for reliable DNA testing. These factors continue to support the segment’s leading position in the U.S. market.
The contract research & testing organizations segment held the second-largest share of 26.00% of the market in 2025 and is expected to grow at the fastest CAGR of 8.27% during the forecast period because many pharmaceutical and biotechnology companies outsource testing services to reduce costs and improve efficiency. These organizations provide specialized expertise, advanced laboratory technologies, and regulatory support throughout product development and manufacturing. Growing demand for biologics, cell and gene therapies, and biosimilars is increasing the need for reliable third-party testing services. Rising outsourcing activities and expanding research projects are expected to drive the fastest growth of this segment during the forecast period.
The academic & research institutions segment held a significant U.S. residual DNA testing market share of 12.00% in 2025 because universities and research centers play an important role in developing new biologics, vaccines, and gene therapies. Residual DNA testing supports research by ensuring the quality and safety of experimental products before they move toward clinical development. Increasing government funding, growing collaborations with pharmaceutical companies, and rising research activities in molecular biology and biotechnology continue to strengthen demand for advanced DNA testing solutions across academic and research laboratories in the U.S.
The regulatory & reference laboratories segment held a significant market share of 9.00% in 2025 because these laboratories help verify product quality, support regulatory compliance, and perform independent testing when required. They play an important role in ensuring that biologics, vaccines, and other advanced therapies meet established safety and quality standards. Increasing regulatory oversight, growing production of biopharmaceutical products, and rising demand for standardized testing methods continue to support the use of residual DNA testing in these laboratories across the U.S.
| Segment | Share 2025 (%) |
| Final Drug Substance/Formulation | 44% |
| Fill-Finish Samples | 19% |
| Upstream Harvest/Cell Culture Supernatants | 15% |
| Downstream Intermediates (Purification Pools) | 13% |
| Raw Materials & In-Process Controls | 9% |
The Final Drug Substance/Formulation Segment Led the Market in 2025
The final drug substance/formulation segment led the U.S. residual DNA testing market in 2025, with a share of 44.00%, because testing at the final production stage is essential to ensure product safety, purity, and compliance with regulatory standards before products reach patients. Pharmaceutical and biotechnology companies perform residual DNA testing to confirm that unwanted genetic material has been removed during manufacturing. The increasing production of biologics, vaccines, biosimilars, and cell and gene therapies has strengthened the demand for final product testing. Strict quality requirements and growing regulatory oversight continue to support the segment’s leading position in the U.S. market.
The fill-finish samples segment held the second-largest share of 19.00% of the market in 2025 and is expected to grow at the fastest CAGR of 8.03% during the forecast period because this stage is critical for ensuring product quality before packaging and distribution. Residual DNA testing helps detect any remaining contaminants and confirms that products meet safety and regulatory requirements. The growing production of biologics, vaccines, and advanced therapies has increased the need for testing during the fill-finish process. Rising investments in sterile manufacturing facilities and expanding biopharmaceutical production are expected to drive the fastest growth of this segment during the forecast period.
The upstream harvest/cell culture supernatants segment held a significant market share of 15.00% in 2025 because testing at this stage helps monitor the amount of host cell DNA generated during the early manufacturing process. Early detection allows manufacturers to improve purification efficiency and maintain consistent product quality. Increasing production of biologics and cell-based therapies has strengthened the need for routine monitoring during upstream processing. Growing adoption of advanced biomanufacturing technologies and stronger quality control practices continues to support demand for residual DNA testing in this segment.
The downstream intermediates (purification pools) segment held a significant U.S. residual DNA testing market share of 13.00% in 2025 because manufacturers must confirm that purification processes effectively remove unwanted DNA before final product formulation. Residual DNA testing at this stage helps improve product quality, manufacturing consistency, and regulatory compliance. As the production of biologics, vaccines, and gene therapies continues to expand, companies are placing greater focus on process validation and quality assurance. These factors continue to increase the importance of residual DNA testing during downstream purification across the United States.
The raw materials & in-process controls segment held a significant market share of 9.00% in 2025 because manufacturers regularly test raw materials and monitor production processes to prevent contamination and maintain consistent product quality. Residual DNA testing helps identify potential issues early, reducing manufacturing risks and supporting efficient production. The growing demand for biologics, vaccines, and advanced therapies has increased the need for stronger quality control throughout manufacturing. Strict regulatory requirements and greater focus on process reliability continue to drive demand for testing at this stage across the United States.
The global residual DNA testing market was valued at US$ 310 million in 2024 and increased to US$ 328.48 million in 2025. It is projected to grow steadily, reaching US$ 552.93 million by 2034, with a compound annual growth rate (CAGR) of 5.96% from 2025 to 2034.
The U.S. pharmaceutical sector is experiencing noteworthy growth due to the growing demand for innovative and personalized treatments. Increasing advanced research and development is significant for emerging novel drugs that treat and manage various types of diseases, and create novel medicines and vaccines, which increases the demand for residual DNA testing. Growing early adoption of advanced technology, such as NGS, qPCR, and digital PCR, for accurate testing. Increasing healthcare institution and contract research centers also drives the growth of the market. As of 2024, there were 4,321 CRO businesses in the United States.
For Instance,
| Company | Key Offerings | Contribution in the Market | Major End-Users |
| Thermo Fisher Scientific | qPCR systems, PCR reagents, DNA quantification kits, analytical instruments | Expands high-throughput testing, supports biologics manufacturing, and strengthens quality control across pharmaceutical production. | Pharma, biotech, CROs |
| Merck KGaA (MilliporeSigma) | Residual DNA assay kits, sample preparation products, analytical services | Improves regulatory compliance and supports safe biologics, vaccines, and cell therapy manufacturing. | Biopharma manufacturers |
| Roche | qPCR platforms, molecular diagnostics, automation solutions | Enhances sensitive DNA detection and increases laboratory efficiency through advanced molecular technologies. | Clinical and research laboratories |
| Bio-Rad Laboratories | Digital PCR systems, PCR reagents, DNA analysis solutions | Advances precise DNA quantification and supports development of next-generation biologics and gene therapies. | Pharma, biotech, academic institutes |
| Agilent Technologies | Genomic analysis instruments, NGS workflows, laboratory automation | Strengthens quality testing with reliable analytical tools and improves workflow efficiency. | Research laboratories, manufacturers |
| Charles River Laboratories | Residual DNA testing, analytical testing, regulatory support | Helps manufacturers meet regulatory standards through outsourced testing and validation services. | Biopharma companies |
| Eurofins Scientific | Contract testing, molecular analysis, GMP laboratory services. | Expands testing capacity and provides specialized residual DNA testing for biologic products. | Pharmaceutical companies |
| Sartorius AG | Bioprocess solutions, sample preparation, laboratory technologies | Supports efficient manufacturing and reliable residual DNA testing during biologics production. | Biotech manufacturers |
| Revvity (PerkinElmer) | Molecular detection reagents, automation, genomic analysis tools | Improves testing accuracy and laboratory productivity through integrated molecular workflows. | Research institutes, pharmaceutical firms |
| Lonza Group | Cell and gene therapy manufacturing, analytical testing, quality services | Supports advanced therapy production by integrating residual DNA testing with biomanufacturing and quality assurance processes | Cell and gene therapy developers. |
In April 2025, Shakti Ramkissoon, M.D., Ph.D., vice president, medical lead for oncology at Labcorp, stated, “With the expansion of our portfolio to include Labcorp Plasma Detect for clinical use and the availability of PGDx elio plasma focus Dx to support patient treatment selection, we're advancing care across the oncology spectrum, solidifying our commitment to transforming cancer diagnostics and improving patient outcomes.”
By Technology
By Product & Service
By Application
By End User
By Sample Type
Principal Consultant
Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.
Learn more about Payal Rabde
Reviewed By
Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.
Learn more about Aditi Shivarkar
